Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cybin Inc N.CYBN

Alternate Symbol(s):  CYBN

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.


NEO:CYBN - Post by User

Post by 88guy88on Nov 18, 2020 3:09pm
785 Views
Post# 31924092

Our Study

Our Study120 people with depression tested with psilocybin strips over 4 month trial in early 2021.....Numinus study is 30 people with additions like smoking and alcohol and this study falls under compassionate study approval by Health Canada as psilocybin is still illegal in Canada....Revive has a strip application and has collaborated with PHRM (which is down 16% today on the news)..you would think it would be up but its not

a few companies starting to come to the front for trials to show benefits of psilocybin

lets hope Cybin is a winner....apprears to have a lot of instututional support and the IPO was oversubscribed with a number of quality management and advisors....will just have to see how it plays out....all cashed up 45 million and ready to rock n roll
<< Previous
Bullboard Posts
Next >>